Yang Danrong, Xue Jianjun, Ma Wenxia, Liu Furong, Fan Yameng, Rong Jie, Yang Aimin, Yu Yan
School of Public Health, Xi'an Jiaotong University Health Science Center.
Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
Nucl Med Commun. 2018 Jan;39(1):16-21. doi: 10.1097/MNM.0000000000000770.
I therapy is a choice for Graves' hyperthyroidism. Several factors that affect the success of I treatment in Graves' disease (GD) patients have been put forward. The aim of this retrospective study was to evaluate the factors influencing the success of I therapy and the occurrence of hypothyroidism after I therapy.
We reviewed 325 GD patients, who were well documented out of 779 cases, treated with I in the First Affiliated Hospital of Xi'an Jiaotong University between 2010 and 2016. We collected the potential influencing factors, including demographic data (age, sex, family history), iodine intake state, antithyroid drugs (ATD) taking, thyroid texture, complications of hyperthyroidism, physical and laboratory examinations [thyroid weight, effective I half-life time (Teff), 24-h iodine uptake rate, tri-iodothyronine, thyroxine, free tri-iodothyronine (FT3), free thyroxine, thyroid-stimulating hormone, thyroglobulin antibody, thyroid microsome antibody, thyrotropin receptor antibody], and final administered dosages according to Quimby formula. The correlations between the prognosis of GD patients and these factors were analyzed by logistic regression analysis.
Out of 325 patients, 247 (76.00%) were treated successfully with radioiodine. GD patients who were cured by I therapy were more likely to have smaller thyroid [odds ratio (OR)=0.988, 95% confidence interval (CI)=0.980-0.996, P=0.002], lower FT4 levels (OR=0.993, 95% CI=0.988-0.997, P=0.002), and shorter time of ATD withdrawal before I treatment (OR=0.985, 95% CI=0.975-0.996, P=0.002). Hypothyroidism occurred in 132 (41.00%) out of 325 patients. There was an increased risk of early hypothyroidism in patients with lower 24-h iodine uptake (OR=0.964, 95% CI=0.941-0.988, P=0.004), and treated with a lower total dose of iodine (OR=0.892, 95% CI=0.824-0.965, P=0.005) and a higher iodine dose per garm of thyroid tissue (OR=5.414E+14, 95% CI=45.495-6.444E+27, P=0.027).
Our results showed that I treatment was more successful in patients with lower weight of the thyroid, lower free thyroxine level, and shorter ATD taking period. Furthermore, early hypothyroidism after radioiodine treatment was more likely to occur in patients with lower 24-h iodine uptake, lower total dose of iodine, and higher iodine dose per garm of thyroid tissue.
碘-131治疗是格雷夫斯甲亢的一种治疗选择。已经提出了几个影响格雷夫斯病(GD)患者碘-131治疗成功的因素。这项回顾性研究的目的是评估影响碘-131治疗成功的因素以及碘-131治疗后甲状腺功能减退的发生情况。
我们回顾了2010年至2016年间在西安交通大学第一附属医院接受碘-131治疗的779例患者中的325例有详细记录的GD患者。我们收集了潜在的影响因素,包括人口统计学数据(年龄、性别、家族史)、碘摄入状态、抗甲状腺药物(ATD)服用情况、甲状腺质地、甲亢并发症、体格检查和实验室检查[甲状腺重量、有效碘半衰期(Teff)、24小时碘摄取率、三碘甲状腺原氨酸、甲状腺素、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素、促甲状腺激素、甲状腺球蛋白抗体、甲状腺微粒体抗体、促甲状腺激素受体抗体],以及根据昆比公式最终给予的剂量。通过逻辑回归分析分析GD患者的预后与这些因素之间的相关性。
在325例患者中,247例(76.00%)经放射性碘治疗成功。经碘-131治疗治愈的GD患者更可能甲状腺较小[比值比(OR)=0.988,95%置信区间(CI)=0.980-0.996,P=0.002]、FT4水平较低(OR=0.993,95%CI=0.988-0.997,P=0.002)以及碘-131治疗前停用ATD的时间较短(OR=0.985,95%CI=0.975-0.996,P=0.002)。325例患者中有132例(41.00%)发生甲状腺功能减退。24小时碘摄取较低的患者发生早期甲状腺功能减退的风险增加(OR=0.964,95%CI=0.941-0.988,P=0.004),并且接受的碘总剂量较低(OR=0.892,95%CI=0.824-0.965,P=0.005)以及每克甲状腺组织的碘剂量较高(OR=5.414E+14,95%CI=45.495-6.444E+27,P=0.027)。
我们的结果表明,甲状腺重量较低、游离甲状腺素水平较低以及服用ATD时间较短的患者碘-131治疗更成功。此外,放射性碘治疗后早期甲状腺功能减退更可能发生在24小时碘摄取较低、碘总剂量较低以及每克甲状腺组织碘剂量较高的患者中。